Workflow
高盛：巨子生物-近期不确定性影响可控；重申 2025 财年指引，ProBio 业务复苏
GIANT BIOGENEGIANT BIOGENE(HK:02367) Goldman Sachs·2025-06-25 13:03

24 June 2025 | 11:25PM HKT Giant Biogene Holding (2367.HK): Business Update: Containable impact from recent uncertainty; Reiterate FY25 guidance expecting Post recent uncertainty, Giant Biogene posted a follow up announcement on night of Jun 23 and hosted a virtual meeting to provide recent business update on Jun 24. Core message is reiterating FY25 full year guidance, i.e. sales/NI up 25-28%/21-24% yoy at RMB6.9-7.1bn/2.5-2.6bn (vs. GSe of RMB6.85bn/2.35bn) despite the ST disruption of 618 sales. The under ...